Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX)
(Delayed Data from NSDQ)
$7.13 USD
+0.33 (4.85%)
Updated Aug 8, 2025 03:59 PM ET
After-Market: $7.13 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BDRX 7.13 +0.33(4.85%)
Will BDRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BDRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BDRX
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock
BDRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the Upgrade
Other News for BDRX
ADR Ratio Change Effective | BDRX Stock News
Biodexa Pharmaceuticals (BDRX) Trading Halted with Pending News
Biodexa Pharmaceuticals PLC-ADR trading halted, news pending
How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover ...
Biodexa Pharmaceuticals announces 1-for-10 reverse ADR split to regain Nasdaq compliance